These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30847774)

  • 1. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
    Arai N; Homma M; Abe M; Baba Y; Murai S; Watanuki M; Kawaguchi Y; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Saito B; Shiozawa E; Harada H; Yamochi-Onizuka T; Nakamaki T; Takimoto M
    Int J Hematol; 2019 May; 109(5):539-544. PubMed ID: 30847774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of CD123 expression in adult AML with normal karyotype.
    Jiang G; Atenafu EG; Capo-Chichi JM; Minden MD; Chang H
    Br J Haematol; 2020 Jan; 188(1):181-184. PubMed ID: 31758553
    [No Abstract]   [Full Text] [Related]  

  • 3. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
    Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
    Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression and Clinical Significance of Leukemia Stem Cell Antigen in Acute Myeloid Leukemia].
    Yao DD; Han BQ; Han YF; Zhang YQ; Jin YL; Dai HB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1583-1588. PubMed ID: 30501688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
    Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
    Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Lamble AJ; Eidenschink Brodersen L; Alonzo TA; Wang J; Pardo L; Sung L; Cooper TM; Kolb EA; Aplenc R; Tasian SK; Loken MR; Meshinchi S
    J Clin Oncol; 2022 Jan; 40(3):252-261. PubMed ID: 34855461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
    Kandeel EZ; Madney Y; Eldin DN; Shafik NF
    Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD16
    Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
    Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.
    Vergez F; Green AS; Tamburini J; Sarry JE; Gaillard B; Cornillet-Lefebvre P; Pannetier M; Neyret A; Chapuis N; Ifrah N; Dreyfus F; Manenti S; Demur C; Delabesse E; Lacombe C; Mayeux P; Bouscary D; Recher C; Bardet V
    Haematologica; 2011 Dec; 96(12):1792-8. PubMed ID: 21933861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 17. Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia.
    Kandeel EZ; El Sharkawy N; Hanafi M; Samra M; Kamel A
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):383-393. PubMed ID: 32201129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
    Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
    Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.